How OFEV
Can Help

Home Why Choose OFEV? How OFEV Can Help

OFEV® (nintedanib) may help those living with idiopathic pulmonary fibrosis (IPF) by slowing the decline in lung function and reducing the risk of an acute exacerbation. Scroll down to read more.

HELPED REDUCE RATE OF
LUNG FUNCTION DECLINE

OFEV slowed the decline in lung function in 3 out of 3 medical studies. In all 3 studies, patients taking 150mg of OFEV twice daily were compared to patients who did not take OFEV (these patients took a placebo, which is a sugar pill). Results were determined by measuring participants’ forced vital capacity (FVC) and the time to a first acute exacerbation during each 1-year study.

This graph shows that patients taking OFEV (the orange lines) experienced about 50% less decline in lung function than those not taking OFEV (the blue lines).

OFEV Clinical Studies 2 and 3

This graph shows that participants taking OFEV (the orange line) experienced 68% less decline in lung function than those not taking OFEV (the blue line).

OFEV Clinical Study 1

HELPED MAINTAIN
LUNG FUNCTION

OFEV Helped Maintain Lung Function in Study 2 OFEV Helped Maintain Lung Function in Study 2

Lung function maintained or showed no decline in 30% of patients taking OFEV

Lung function was measured by FVC during the 1-year study. This graph shows that, at the end of 1 year, 30% of participants taking OFEV (the orange bar) maintained their lung function compared to 18% of those not taking OFEV (the blue bar). Study 3 showed similar results.

HELPED REDUCE RISK OF AN
ACUTE EXACERBATION

In two out of three medical studies, OFEV significantly reduced the chances of having a first acute exacerbation during a 1-year period. The other trial’s results showed no effect of OFEV on acute exacerbations.


OFEV Helped Reduce Risk of an Acute Exacerbation

In one of the two studies, participants taking OFEV were 80% less likely to have an acute exacerbation during a 1-year period than those not taking OFEV (7.3% of patients taking OFEV, compared to 1.5% of patients not taking OFEV, with an absolute difference of 5.8%).

OFEV Helped Reduce Risk of an Acute Exacerbation
Sharon, OFEV Mentor, Wife of Someone with IPF

“Jerry having IPF was not something we could control, but learning more about it and doing what we can to slow its progression, by taking OFEV, are things that we can control.”

Sharon, OFEV Mentor, Wife of Someone with IPF

Sharon, OFEV Mentor, Wife of Someone with IPF